Figure 6 Combination therapy for HCC

Slides:

Advertisements

Similar presentations

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Advertisements

Volume 71, Issue 2, Pages (February 2017)

Figure 5 Dendritic cells in liver inflammation

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Clinical options for HCC therapy

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Classification of immunotherapies

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Molecular approaches to HER2 targeted therapy

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Diverse molecular mechanisms of long non-coding RNAs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 The role of CTLA4 and PD1 in T cell activation

Targets for immunotherapy of liver cancer

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 2 Site of action of checkpoint inhibitors and agonists being

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Figure 7 T cells in liver inflammation

Figure 6 Innate lymphoid cells in liver inflammation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Systems biological model of IBS

Nat. Rev. Endocrinol. doi: /nrendo

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Mechanisms of action of immunotherapy modalities

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Presentation transcript:

Figure 6 Combination therapy for HCC Figure 6 | Combination therapy for HCC. Combination of internal and systemic approaches avoids the toxicity risk of concurrent intravenous administration of several mAbs. Abbreviations: CTLA-4, cytotoxic T-lymphocyte protein 4; HCC, hepatocellular carcinoma; mAb, monoclonal antibody; PD-1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1. Prieto, J. et al. (2015) Immunological landscape and immunotherapy of hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2015.173